JAK1 and COVID-19: In the latter case, the recent ACTT-2 trial comparing remdesivir with and without baricitinib, a JAK1/2 immunomodulator, have shown modest additional reductions in mortality in hospitalized patients with severe COVID-19 not yet on mechanical ventilation [57].